RISEDRONATE SODIUM - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for risedronate sodium and what is the scope of freedom to operate?

Risedronate sodium is the generic ingredient in three branded drugs marketed by Apil, Impax Labs Inc, Sun Pharm, Teva Pharms Usa, Zydus Pharms, Apotex, Aurobindo Pharma, Aurobindo Pharma Ltd, Hangzhou Binjiang, Macleods Pharms Ltd, Norvium Bioscience, and Orbion Pharms, and is included in sixteen NDAs. There are three patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Risedronate sodium has eighty-four patent family members in thirty-three countries.

There are seventeen drug master file entries for risedronate sodium. Thirteen suppliers are listed for this compound.

Summary for RISEDRONATE SODIUM

International Patents:	84
US Patents:	3
Tradenames:	3
Applicants:	12
NDAs:	16
Drug Master File Entries:	17
Finished Product Suppliers / Packagers:	13
Raw Ingredient (Bulk) Api Vendors:	87
Clinical Trials:	16
Patent Applications:	3,588
Drug Prices:	Drug price trends for RISEDRONATE SODIUM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RISEDRONATE SODIUM
What excipients (inactive ingredients) are in RISEDRONATE SODIUM?	RISEDRONATE SODIUM excipients list
DailyMed Link:	RISEDRONATE SODIUM at DailyMed

See drug prices for RISEDRONATE SODIUM

Recent Clinical Trials for RISEDRONATE SODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sheffield Children's NHS Foundation Trust	Phase 2
Takeda
Chugai Pharmaceutical	Phase 3

See all RISEDRONATE SODIUM clinical trials

Pharmacology for RISEDRONATE SODIUM

Drug Class	Bisphosphonate

Medical Subject Heading (MeSH) Categories for RISEDRONATE SODIUM

Bone Density Conservation Agents
Calcium Channel Blockers

Paragraph IV (Patent) Challenges for RISEDRONATE SODIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ATELVIA	Delayed-release Tablets	risedronate sodium	35 mg	022560	1	2011-06-09
ACTONEL	Tablets	risedronate sodium	150 mg	020835	1	2008-08-12
ACTONEL	Tablets	risedronate sodium	75 mg	020835	1	2007-09-07
ACTONEL	Tablets	risedronate sodium	5 mg, 30 mg and 35 mg	020835	1	2004-04-23

US Patents and Regulatory Information for RISEDRONATE SODIUM

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Norvium Bioscience	RISEDRONATE SODIUM	risedronate sodium	TABLET;ORAL	200477-002	Nov 30, 2015		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Macleods Pharms Ltd	RISEDRONATE SODIUM	risedronate sodium	TABLET;ORAL	203533-002	Dec 9, 2015	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Apil	ATELVIA	risedronate sodium	TABLET, DELAYED RELEASE;ORAL	022560-001	Oct 8, 2010	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Apil	ATELVIA	risedronate sodium	TABLET, DELAYED RELEASE;ORAL	022560-001	Oct 8, 2010	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Apotex	RISEDRONATE SODIUM	risedronate sodium	TABLET;ORAL	090877-002	Jun 10, 2014	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Teva Pharms Usa	RISEDRONATE SODIUM	risedronate sodium	TABLET, DELAYED RELEASE;ORAL	203217-001	May 18, 2015	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Teva Pharms Usa	RISEDRONATE SODIUM	risedronate sodium	TABLET;ORAL	079215-001	Jun 13, 2014	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for RISEDRONATE SODIUM

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-002	Apr 14, 2000	⤷ Sign Up	⤷ Sign Up
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-004	Apr 16, 2007	⤷ Sign Up	⤷ Sign Up
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-003	May 25, 2002	⤷ Sign Up	⤷ Sign Up
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-003	May 25, 2002	⤷ Sign Up	⤷ Sign Up
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-002	Apr 14, 2000	⤷ Sign Up	⤷ Sign Up
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-004	Apr 16, 2007	⤷ Sign Up	⤷ Sign Up
Apil	ACTONEL	risedronate sodium	TABLET;ORAL	020835-003	May 25, 2002	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for RISEDRONATE SODIUM

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Slovenia	1753395		⤷ Sign Up
Portugal	2269584		⤷ Sign Up
European Patent Office	1753395	ENTERIC SOLID ORAL DOSAGE FORM OF A BISPHOSPHONATE CONTAINING A CHELATING AGENT	⤷ Sign Up
Germany	602005022578		⤷ Sign Up
South Korea	20080083068		⤷ Sign Up
Argentina	098686		⤷ Sign Up
Morocco	29681		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.